Division of Hematology/Oncology, University of Virginia, PO Box 800716, Charlottesville, VA, 22908, USA.
Division of Thoracic Cardiovascular Surgery, University of Virginia, Charlottesville, VA, USA.
Curr Oncol Rep. 2020 Aug 15;22(11):109. doi: 10.1007/s11912-020-00969-w.
Immunotherapy has revolutionized the treatment of non-surgical stage III and stage IV non-small cell lung cancer (NSCLC). Here, we review emerging data on the safety, feasibility, and efficacy of neoadjuvant immunotherapy in the setting of earlier stage surgically resectable lung cancer.
Several small studies support the safety and feasibility of neoadjuvant immunotherapy, noting similar perioperative rates of morbidity and mortality compared with historical controls. Data from several phase II trials have shown high rates of major pathologic response (MPR), though it is unclear if this will correlate with a survival benefit. Phase III trials of neoadjuvant immunotherapy alone or in combination with chemotherapy are ongoing. Neoadjuvant immunotherapy offers a promising treatment modality in earlier stage NSCLC patients. Results of ongoing phase II and phase III trials will be essential in determining how to best integrate this treatment modality in the future.
免疫疗法彻底改变了 III 期和 IV 期非小细胞肺癌（NSCLC）的治疗方法。在此，我们回顾了早期可手术切除肺癌新辅助免疫治疗的安全性、可行性和疗效的最新数据。
几项小型研究支持新辅助免疫治疗的安全性和可行性，与历史对照相比，注意到类似的围手术期发病率和死亡率。来自几项 II 期试验的数据显示了高比例的主要病理缓解（MPR），尽管尚不清楚这是否与生存获益相关。新辅助免疫单药或联合化疗的 III 期试验正在进行中。新辅助免疫治疗为早期 NSCLC 患者提供了一种很有前途的治疗方式。正在进行的 II 期和 III 期试验的结果对于确定如何在未来最好地整合这种治疗方式至关重要。
